Market News & Trends
NodThera’s NLRP3 Inhibitor Meets Primary Endpoint of Inflammation Reversal in Phase 1b/2a Trial in Obese Subjects With Cardiovascular Risk
NodThera recently announced positive data from its Phase 1b/2a cardiovascular risk study in inflamed obese subjects, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome…
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte Therapy
KSQ Therapeutics, Inc. recently announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of…
XOMA Receives $8.1-Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
XOMA Corporation recently announced it has received an $8.1-million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority…
Wave Life Sciences Announces Presentations Highlighting Novel siRNA Program in Obesity & Leadership in RNA Editing
Wave Life Sciences Ltd. recently announced presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit,…
MD Anderson & Sibylla Biotech Announce Strategic Collaboration to Discover & Develop Small Molecule Protein Degraders
The University of Texas MD Anderson Cancer Center and Sibylla Biotech recently announced a strategic collaboration agreement to discover and develop novel small molecule cancer…
Sermonix Pharmaceuticals Announces Breast Cancer Research Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
Sermonix Pharmaceuticals Inc. recently announced the publication of its scholarly article Lasofoxifene as a Potential Treatment for Aromatase Inhibitor-Resistant ER-Positive Breast Cancer, in the peer-reviewed…
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, recently announced that…
Spherix Global Insights Expands Therapeutic Area Coverage Into Hematology
Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth…..
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild-to-Moderate Alopecia Areata
SiSaf Ltd recently announced that a licensee of the ProSilic variant of its technology has reported positive topline results from a randomized, placebo-controlled, multi-dose Phase 2…
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate
Assembly Biosciences, Inc. recently announced the first participant has been dosed in the Phase 1a/b trial of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor…
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA & EMA
MoonLake Immunotherapeutics recently announced the successful outcome of its end-of-Phase 2 interactions with the US FDA as well as positive feedback from its interactions with…
CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation
CordenPharma and Certest have signed a partnership agreement on May 7, 2024, which aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the missing….
Atriva Therapeutics Secures US Patent for First-in-Class Broad Spectrum Therapy for Severe RNA Virus Infections Including Bird Flu
Atriva Therapeutics recently announced it has been granted a US patent for its MEK inhibitor zapnometinib (ATR-002). The patent includes claims for the treatment of…
Vetter Announces Plans to Expand its Capacity in the US & Germany
The move will effectively double the capacity of Vetter Development Services in the US and provide ample space for future expansion opportunities…..
CERo Therapeutics Successfully Completes IND-Enabling Toxicology Studies for Lead Compound
CERo Therapeutics Holdings, Inc. recently announced the successful completion of toxicology studies for its lead compound, CER-1236. The toxicology studies will be included in the…
ArriVent Announces Multi-Target ADC Collaboration With Alphamab
ArriVent BioPharma, Inc. recently announced it has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. to discover, develop and commercialize novel antibody…
Ocean Biomedical Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results
Ocean Biomedical, Inc. congratulated its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the…
Nucleus RadioPharma Secures Series A Extension Funding With AstraZeneca Investment
Nucleus RadioPharma recently announced the closing of a Series A extension round with new investor AstraZeneca. AstraZeneca joins existing investors from GE Healthcare, Mayo Clinic,…
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor
Assembly Biosciences, Inc. recently announced new data for ABI-6250, the company’s orally bioavailable, small molecule hepatitis D virus (HDV) entry inhibitor candidate, featured in a…
Gerresheimer to Acquire Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group
Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biotech industries….
